Full-Time
Key Account Manager
Hepatology
Updated on 9/4/2026
Mirum Pharmaceuticals
201-500 employees
ASBT inhibitors for rare liver diseases
No salary listed
Remote in Germany
Hybrid
Remote within Germany, with frequent travel including overnight travel required.
Bachelor's
 Sales & Account Management (1) |
|---|
Get referred to Mirum Pharmaceuticals
See people who can refer or advise you
- A bachelor's degree in science or a related field is required.
- At least 3 years of professional experience in pharmaceutical or biotechnology field-based commercial roles is required.
- A proven track record of delivering results in specialty care or rare disease markets is required.
- Demonstrated success supporting product launch, growth, or market-development activities in complex healthcare environments is required.
- Understanding of strategic account management, regional healthcare structures, and the German healthcare environment is required.
- Commitment to compliance, ethical business practices, and appropriate scientific exchange is required.
- Willingness to travel frequently, including overnight travel, is required.
- Fluency in German and English is required, including the ability to read, understand, and communicate scientific and business information in English.
- Strong strategic account thinking, prioritization, and follow-through skills are required.
- Effective influencing, stakeholder management, and relationship-building skills are required.
- Strong clinical acumen and commitment to continuous learning are required.
- Develop and execute strategic account plans for priority centers and regional networks aligned with national commercial objectives.
- Build trusted partnerships with healthcare professionals, key opinion leaders, specialist centers, academic hospitals, and multidisciplinary care teams across the assigned region.
- Deliver high-quality scientific and product discussions that support appropriate patient care.
- Identify customer needs and align company resources and solutions to support appropriate patient care.
- Continuously assess regional account opportunities using customer insights, market intelligence, and business data.
- Support account-readiness activities by identifying awareness, diagnostic pathway, and referral-process gaps within priority accounts and regional networks.
- Share compliant field insights to support market development, account readiness, and future launch planning.
- Collaborate with Medical Affairs, Market Access, Marketing, and other cross-functional colleagues.
- Maintain strong knowledge of relevant disease states, the treatment landscape, and company products.
- Demonstrate accountability for territory performance while operating in compliance with company policies and applicable regulations.
- Share best practices and support team success.
- An advanced degree is preferred.
- Experience in liver disease, rare disease, gastrointestinal, hepatology, or related specialty areas is preferred.
Mirum Pharmaceuticals develops and commercializes therapies for rare liver diseases. Its lead drug LIVMARLI (maralixibat) is an oral ASBT inhibitor that lowers bile acid buildup to relieve itching in cholestatic conditions such as Alagille syndrome, and the company is pursuing LIVMARLI for additional rare liver diseases, with volixibat as another ASBT inhibitor in its pipeline. The company differentiates itself by focusing on rare pediatric and adult cholestatic diseases and building dedicated commercialization infrastructure in the U.S. and other major markets, including partnerships with physicians, payers, and patient groups to improve patient access. Mirum’s goal is to bring effective therapies to patients with rare bile-duct and liver disorders, expand LIVMARLI indications, and establish a sustainable market presence in key markets.
Company Size
201-500
Company Stage
IPO
Headquarters
Foster City, California
Founded
2018
Get referred to Mirum Pharmaceuticals
See people who can refer or advise you
Simplify's Take
What believers are saying
- Q2 2026 net product sales reached $176.2 million, and guidance rose to $700 million.
- Rob Myers starts September 21, 2026, strengthening hepatology leadership before key readouts.
- Volixibat, brelovitug, and zilurgisertib create multiple catalysts through first-half 2027.
What critics are saying
- FDA recommended another volixibat Phase 3 on August 5, 2026, delaying PSC filing.
- If LIVMARLI growth slows, Mirum loses the cash engine funding its pipeline.
- Zilurgisertib’s September 26, 2026 PDUFA denial would crush sentiment and financing flexibility.
What makes Mirum Pharmaceuticals unique
- LIVMARLI dominates rare pediatric cholestatic disease with expanding PFIC and biliary atresia labels.
- Mirum combines commercialization strength with late-stage hepatology pipeline breadth across PSC, HDV, and FOP.
- Exclusive zilurgisertib rights from Incyte add a near-term rare-disease launch platform.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Hybrid Work Options
Growth & Insights and Company News
6 month growth
↑ 0%1 year growth
↓ -1%2 year growth
↑ 0%Mirum Pharmaceuticals has appointed Dr Rob Myers as chief medical officer, effective 21 September 2026. Dr Myers will lead the company's global medical and clinical development functions. Dr Myers brings over 20 years of experience in drug development, with particular expertise in hepatology. He joins from OrsoBio, where he served as chief medical officer and head of development. Previously, he held senior leadership positions at Gilead Sciences, overseeing clinical development programmes across liver fibrosis, cholestatic liver diseases, and gastrointestinal inflammation. Dr Myers has published more than 200 peer-reviewed papers and has contributed to advancing understanding of primary sclerosing cholangitis. He holds an MD from Western University and a master's degree in epidemiology from the University of Calgary.
US FDA approves Regeneron's rare bone disorder drug. Regeneron's Pasatru has received US FDA approval for adults with FOP after clinical trials showed a significant reduction in abnormal bone formation. By Reuters August 20, 2026, 8:59:40 AM IST (Published) The US FDA on Wednesday (August 19) approved Regeneron's drug for a rare genetic disorder after it significantly reduced abnormal bone formation in certain soft tissues. New York-based Regeneron's shares rose 4%. The drug, garetosmab, branded as Pasatru, was approved to treat adults with fibrodysplasia ossificans progressiva (FOP) - a condition in which muscle, tendon and ligament tissue gradually turns into bone, leading to a "second skeleton" that causes progressive loss of mobility and reduced life expectancy. In a 56-week trial involving 63 participants, Pasatru reduced the development of new bone abnormalities by 94% in patients treated with a 3 mg per kg dose and by 90% in those given a 10 mg per kg dose, compared with a placebo. The drug works by blocking Activin A, a protein involved in triggering abnormal bone growth in patients with FOP. Susan Rhee, a member of Regeneron's clinical team, told Reuters last week that the company plans to start a trial for children later this year. The drug will compete with French drugmaker Ipsen's oral treatment Sohonos, which in 2023 became the only other treatment approved by the US Food and Drug Administration. Incyte and partner Mirum Pharma, as well as privately held Ashibio, are also developing treatments for the condition. In 2020, Regeneron paused dosing in a mid-stage trial of the drug after five patient deaths, ultimately discontinuing the study and working with global regulators to design the late-stage trial, according to the company. The condition affects roughly 1 in 2 million people worldwide, with around 800 to 900 active diagnosed cases globally, according to data from the National Institutes of Health.
Mirum Pharmaceuticals shares plunged 15% on Thursday after the FDA recommended an additional Phase 3 study for its liver disease candidate Volixibat, potentially delaying the new drug application until the first half of 2027. Citizens lowered its price target to $137 from $146 whilst maintaining an Outperform rating. The regulatory setback overshadowed strong second-quarter results. Mirum reported revenue of $176.2 million, beating analysts' estimates of $167.3 million. The company raised its full-year net product sales guidance to $680 million to $700 million, from $660 million to $680 million. Mirum ended the quarter with $561.3 million in cash and equivalents. Volixibat has already received FDA Breakthrough Therapy and Orphan Drug designations.
Mirum Pharmaceuticals raised its full-year 2026 net product sales guidance to $680 million to $700 million, citing growth in Alagille syndrome and expanding adult PFIC diagnosis. The company secured $690 million through a convertible note offering, improving its capital structure whilst settling 75% of 2029 notes. The firm identified a significant opportunity in adult PFIC, estimating at least 2,000 addressable patients each in the US and Europe. Commercial operations achieved a high-50s percent cash contribution margin, representing a 5 percentage point year-over-year improvement. Mirum delayed its volixibat PSC NDA submission due to alignment issues with FDA reviewers but received Breakthrough Therapy Designation. The company targets a first-half 2027 NDA submission for PSC and anticipates Phase III PBC results in Q1 2027.
Mirum Pharmaceuticals reported revenue of $176.24 million for the quarter ended June 2026, up 37.9% year-over-year. The figure exceeded the consensus estimate of $164.76 million by 6.97%. The company posted a loss of $0.80 per share, compared to $0.12 a year ago, slightly missing the estimated loss of $0.77 per share. Product sales showed strong performance across categories. Livmarli generated $128.72 million, surpassing the $119.6 million analyst estimate. Bile acid medicines brought in $47.52 million, also beating expectations of $45.64 million. Despite beating revenue estimates, Mirum's shares fell 18.7% over the past month, underperforming the S&P 500's 3.5% gain.